Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 138

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 138
---
 is equal to $10.05 per share (which is the assumed redemption price) multiplied by 20,000,000 ordinary shares, which is the maximum number of ordinary shares that may be redeemed for a $10.05 purchase price per share. (4)Actual share amount is prior to any surrender and forfeiture of founder shares by our initial shareholders and as adjusted share amount assumes exercise of the underwriters’ over -allotmentoption. (5)The “as adjusted” additional paid -incapital calculation is equal to the “as adjusted” total shareholders’ deficit of $5,483,159, minus the par value of the ordinary shares of $0.0001, plus the accumulated deficit of $5,484,076.

88 Management’s discussion and analysis of financial condition and res ults of operatio ns Overview We are a blank check company incorporated as an exempted company in the Cayman Islands on May 23, 2024 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. We intend to effectuate our initial business combination using cash from the proceeds of this offering and the sale of the private units, our shares, debt or a combination of cash, shares and debt. The issuance of additional ordinary shares or preference shares in a business combination: •may significantly dilute the equity interest of investors in this offering; •may subordinate the rights of holders of ordinary shares if preference shares are issued with rights senior to those afforded our ordinary shares; •could cause a change of control if a substantial number of ordinary shares are issued, which could result in the resignation or removal of our present directors and officers; •may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; •may adversely affect prevailing market prices for our units, ordinary shares and/or rights. Similarly, if we issue debt or otherwise incur significant indebtedness, it could result in: •default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; •acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when